pharma · Chronic Lymphocytic Leukemia (CLL) · Chronic Lymphocytic Leukemia · APVO
Aptevo Therapeutics
Aptevo Therapeutics trial registry — 10 ClinicalTrials.gov studies with program phase, status, and indication context.
Seattle, USA HQ
2016 Founded
54 Employees
Public company Type
APVO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Seattle, USA
- Founded
- 2016
- Employees
- 54
- Programs
- 9
- Drugs
- 4
- Patents
- 13
Aptevo Therapeutics clinical trials
Registry index of 10 ClinicalTrials.gov studies linked to Aptevo Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Aptevo Therapeutics trial registry — 10 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Aptevo Therapeutics.
-
APVO436 — Phase 1
Clinical update -
TRU-016 (anti-CD37 protein therapeutic) — Phase 1
Clinical update -
TRU-016 and bendamustine — Phase 2
Clinical update -
ALG.APV-527 — Phase 2
Clinical update -
20 mg/kg TRU-016 + Rituximab — Phase 1
Clinical update -
APVO210 — Phase 1
Clinical update -
APVO436 — Phase 1
Clinical update -
ES414 — Phase 1
Clinical update